ViCentra Adds $13 Million to Series D, Lifting Kaleido Funding to $98 Million
The new capital supports a production scale-up to drive European growth.
Overview
- ROM Utrecht Region and Dutch investors including Venturing Tech provided the new funding, with additional participation from existing backer Innovation Industries.
- ViCentra will expand manufacturing and commercial operations in Germany, the Netherlands and France to meet rising demand.
- The company is accelerating preparations for U.S. market access for its next‑generation Kaleido insulin patch pump.
- Kaleido is marketed as a compact, lightweight patch pump with customizable aluminum shells and integrations with Diabeloop’s AID algorithms and Dexcom CGMs.
- ViCentra reports doubling its user base to more than 4,000 in 2025 and is targeting nearly tripling its European community by the end of 2026 while positioning against rivals such as Insulet, Medtronic/MiniMed, Tandem, Beta Bionics, PharmaSens and SiBionics.